Nicoletta Zanaletti
Naples, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Heterogeneous disease and intermittent treatment in metastatic colorectal cancer: A case report.
Journal: Frontiers in oncology
Published: October 30, 2022
Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase II study.
Journal: ESMO open
Published: October 10, 2022
Adjuvant chemotherapy after neoadjuvant chemo-radiotherapy and surgery in locally advanced rectal cancer. A systematic review of literature with a meta-analysis of randomized clinical trials.
Journal: Critical reviews in oncology/hematology
Published: January 19, 2022
Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial.
Journal: JAMA oncology
Published: August 12, 2021
A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?
Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: August 03, 2021
Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study.
Journal: Frontiers in oncology
Published: May 19, 2021
Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis.
Journal: Journal of translational medicine
Published: March 08, 2021
Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study.
Journal: Clinical colorectal cancer
Published: March 02, 2021
Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data.
Journal: Clinical colorectal cancer
Published: December 21, 2020
Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol.
Journal: Therapeutic advances in medical oncology
Published: September 14, 2020
Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study.
Journal: Cancers
Published: April 25, 2020
Last Updated: 09/26/2026